Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
12.40 -0.60 (-4.62%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap326.37M
Revenue (ttm)2.56M
Net Income (ttm)-28.59M
Shares Out26.32M
EPS (ttm)-3.44
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,750
Open13.11
Previous Close13.00
Day's Range12.33 - 14.19
52-Week Range12.23 - 33.99
Betan/a
AnalystsBuy
Price Target39.25 (+216.5%)
Earnings Daten/a

About IMRX

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human ...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOBenjamin J. Zeskind, Ph.D.
Employees36
Stock ExchangeNASDAQ
Ticker SymbolIMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Immuneering stock is "Buy." The 12-month stock price forecast is 39.25, which is an increase of 216.53% from the latest price.

Price Target
$39.25
(216.53% upside)
Analyst Consensus: Buy

News

Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise

1 day ago - GlobeNewsWire

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External...

Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors

1 week ago - GlobeNewsWire

Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...

2 weeks ago - GlobeNewsWire

Immuneering Added to the Nasdaq Biotechnology Index

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...

1 month ago - GlobeNewsWire

Immuneering Announces Participation in December Investor Conferences

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells Highlighting proprietary ...

2 months ago - GlobeNewsWire

Immuneering to Participate in Jefferies 2021 London Healthcare Conference

To highlight proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells To highlight proprietary ...

2 months ago - GlobeNewsWire

Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

2 months ago - GlobeNewsWire

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular ...

Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotoras...

3 months ago - GlobeNewsWire

Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Confe...

Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition

3 months ago - GlobeNewsWire

Immuneering Announces Inclusion in the Russell 2000® Index

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...

3 months ago - GlobeNewsWire

5 Stocks With High Insider Buys Over Past 2 Months

According to the Insider Cluster Buys page, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months are Orange County Bancorp Inc. ( OBT , Financial), FS KKR Capital ...

Other symbols:FSKGABCOBTSSBK
4 months ago - GuruFocus

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

4 months ago - GlobeNewsWire

Immuneering to Participate in September Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...

4 months ago - GlobeNewsWire

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to ...

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...

5 months ago - GlobeNewsWire

Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO

Immuneering Corp (NASDAQ: IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as...

5 months ago - Benzinga

Immuneering Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...

5 months ago - GlobeNewsWire